Form 4: Ocuphire Pharma Director Susan Benton Reports Stock and Option Grants

Director Susan Benton reports the acquisition of restricted stock units and stock options in Ocuphire Pharma.

Summary

• Susan Benton, a director of Ocuphire Pharma, filed a Form 4 on June 13, 2024, reporting transactions that occurred on June 11, 2024.
• Benton acquired 41,143 shares of common stock through a grant of restricted stock units.
• These restricted stock units vest upon the earlier of one year from the grant date or the day prior to the next annual meeting of stockholders, contingent on continued service.
• Benton also acquired options to purchase 35,181 shares of common stock at an exercise price of $1.72.
• These options vest on the same schedule as the restricted stock units and expire on June 10, 2034.
• The filing also includes a Power of Attorney, effective February 1, 2024, authorizing Amy Rabourn and Sharon Goldbach to act on Benton's behalf for SEC filings related to Ocuphire Pharma.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock and option grants, which is neither particularly positive nor negative on its own. The grants align director interests with shareholders.

Positives

• The grant of restricted stock units and options to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages continued service and commitment to the company.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge the sentiment and actions of those with the most knowledge of the company.

Comparison to Industry Standards

• Stock option and RSU grants are a common form of compensation for directors and executives in publicly traded companies, particularly in the pharmaceutical industry.
• Vesting schedules tied to continued service are standard practice to incentivize long-term commitment.
• The specific terms of the grants (number of shares, exercise price, vesting schedule) would need to be compared to those of peer companies to assess their competitiveness.

Stakeholder Impact

• The grants of stock and options to a director can have a positive impact on shareholders by aligning the director's interests with theirs.
• Employees may view the grants as a positive sign of the company's commitment to its leadership.

Key Dates